Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes

  • Widodo, Irianiwati (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Dwianingsih, Ery Kus (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Triningsih, Ediati (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Utoro, Totok (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Soeripto, Soeripto (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Breast cancer is a heterogeneous disease with molecular subtypes that have biological distinctness and different behavior. They are classified into luminal A, luminal B, Her-2 and triple negative/basal-like molecular subtypes. Most of breast cancers reported in Indonesia are already large size, with high grade or late stage but the clinicopathological features of different molecular subtypes are still unclear. They need to be better clarified to determine proper treatment and prognosis. Aim: To elaborate the clinicopathological features of molecular subtypes of breast cancers in Indonesian women. Materials and Methods: A retrospective cross-sectional study of 84 paraffin-embedded tissues of breast cancer samples from Dr. Sardjito General Hospital in Central Java, Indonesia was performed. Expression of ER, PR, Her-2 and Ki-67 was analyzed to classify molecular subtypes of breast cancer by immunohistochemistry. The relation of clinicopathological features of breast cancers with molecular subtypes of luminal A, luminal B, Her-2 and triple negative/basal-like were analyzed using Pearson's Chi-Square test. A p-value of <0.05 was considered statistically significant. Results: Case frequency of luminal A, Luminal B, Her-2+ and triple negative/basal-like subtypes were 38.1%, 16.7%, 20.2% and 25%, respectively. Significant difference was found in breast cancer molecular subtypes in regard to age, histological grade, lymph node status and staging. However it showed insignificant result in regard to tumor size. Luminal A subtype of breast cancer was commonly found in >50 years old women (p:0.028), low grade cancer (p:0.09), negative lymph node metastasis (p:0.034) and stage III (p:0.017). Eventhough the difference was insignificant, luminal A subtype breast cancer was mostly found in small size breast cancer (p:0.129). Her-2+ subtype breast cancer was more commonly diagnosed with large size, positive lymph node metastasis and poor grade. Triple negative/basal-like cancer was mostly diagnosed among <50 years old women. Conclusions: This study suggests that immunohistochemistry-based subtyping is essential to classify breast carcinoma into subtypes that vary in clinicopathological features, implying different therapeutic options and prognosis for each subtype.

Keywords

References

  1. Blows FM, Driver KE, Schmidt MK, et al (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. Plos Med, 7, 1000279. https://doi.org/10.1371/journal.pmed.1000279
  2. Bosch A, Eroles P, Zaragova R, et al (2010). A triple negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev, 36, 206-15. https://doi.org/10.1016/j.ctrv.2009.12.002
  3. Campbell MJ, Tonlaar NY, Garwood ER, et al (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat, 128, 703-11. https://doi.org/10.1007/s10549-010-1154-y
  4. Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes and survival in the caroline breast cancer study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
  5. Chanrion M, Fontaine H, Rodriguez C, et al (2007). A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer, 7, 2407.
  6. Chuthapisith S, Permsapaya W, Warnnissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and Her-2 status in Thai women. Asian Pac J Cancer Prev, 13, 459-62. https://doi.org/10.7314/APJCP.2012.13.2.459
  7. El-Hawary AK, Abbas AS, Elsyayed AA, Zalata KR (2012). Molecular subtypes of breast carcinoma in Egyptian women: Clinicopathological features. Pathology-Research and Practice, 208, 382-6. https://doi.org/10.1016/j.prp.2012.03.011
  8. El Fatemi H, Chahbouni S, Jayi S, et al (2012). Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol, 7, 170-6. https://doi.org/10.1186/1746-1596-7-170
  9. Eroles P, Bosch A, Alejandro Perez-Fidalgo J, Lluch A (2012). Molecular biology in breast cancer: Intrinsic subtypes and signaling pathway. Cancer Treat Rev, 38, 698-707. https://doi.org/10.1016/j.ctrv.2011.11.005
  10. Fan C, Oh DS, Wessels L, et al (2006). Concordance among gene-expression-based predictors for breast cancer. N Eng J Med, 355, 560-9. https://doi.org/10.1056/NEJMoa052933
  11. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Concensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  12. Gnant M, Harbeck N, Thomssen C (2011). St Gallen 2011: Summary of the consensus Discussion. Breast Cancer, 6, 136-41.
  13. Guarneri V, Conte P (2009). Metastatic breast cancer. Therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist, 14, 645-56. https://doi.org/10.1634/theoncologist.2009-0078
  14. Hammond MEH, Hayes DF, Wolff AC, et al. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Practice, 6, 195-7. https://doi.org/10.1200/JOP.777003
  15. Huo D, Ikpatt F, Khramtsov A, et al. (2009). Population differences in breast cancer: survey indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol, 27, 4515-21. https://doi.org/10.1200/JCO.2008.19.6873
  16. Jia WJ, Jia HX, Feng HY, et al (2014). Her-2 enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy. Asian Pac J Cancer Prev, 15, 315-20. https://doi.org/10.7314/APJCP.2014.15.1.315
  17. Kao J, Salari K, Bocanegara M, et al (2009). Molecular profiling of breast cancer cell defines relevant tumor models and provides a resource for cancer gene discovery. PloS One, 4, 6146. https://doi.org/10.1371/journal.pone.0006146
  18. Kadivar M, Mafi N, Joulaee A, et al (2012). Breast cancer molecular subtypes and association with clinicopathological characteristics in Iranian women, 2002-2011. Asian Pac J Cancer Prev, 13, 1881-6. https://doi.org/10.7314/APJCP.2012.13.5.1881
  19. Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013). Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotheraphy in patients with advanced breast cancer. Asian Pac J Cancer Prev, 14, 3223-28 https://doi.org/10.7314/APJCP.2013.14.5.3223
  20. Loe S, Haibe-Kains B, Desmedt C, et al (2007). Definition of clinically distinct molecular subtypes in estrogen receptorpositive breast carcinomas through genomic grade. J Clin Oncol, 25, 1239-46. https://doi.org/10.1200/JCO.2006.07.1522
  21. Milikan RC, Newman B, Tse CK, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39. https://doi.org/10.1007/s10549-007-9632-6
  22. Najafi B, Anvari S, Roshan ZA. (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2002 in Iran. Asian Pac J Cancer Prev, 14, 5811-16. https://doi.org/10.7314/APJCP.2013.14.10.5811
  23. Ontilo AA, Enget JM, Greenlee RT, Mukesh BN. (2008). Breast cancer subtypes based on ER/PR and HER-2/neu expression: Comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7, 4-13.
  24. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52. https://doi.org/10.1038/35021093
  25. Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23. https://doi.org/10.1073/pnas.0932692100
  26. Su Y, Zheng Y, Zheng W, et al (2011). Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer, 11, 292. https://doi.org/10.1186/1471-2407-11-292
  27. Tavassoli FA, Devilee P (2003). WHO Classification of tumours. Pathology and genetics. Tumours of the breast and female genital organs, IARC Press, Lyon.
  28. Widodo I, Ferronika P, Harijadi A, et al (2013). Cinicopathological significance of lymphangiogenesis and tumor lymphovascular invasion in Indonesian breast cancers. Asian Pac J Cancer Prev, 14, 997-1001. https://doi.org/10.7314/APJCP.2013.14.2.997
  29. Wolff AC., Hammond EH, Schwartz KL, et al (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 33, 19-33.

Cited by

  1. Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9327
  2. Comparison of telomere length and insulin-like growth factor-binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in Turkish women vol.31, pp.5, 2017, https://doi.org/10.1002/jcla.22083
  3. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital vol.15, pp.1, 2017, https://doi.org/10.1186/s12957-017-1113-8
  4. The most important questions in cancer research and clinical oncology vol.36, pp.1, 2017, https://doi.org/10.1186/s40880-016-0168-1